Zimberelimab - Arcus Biosciences/Guangzhou Gloria Biosciences/Taiho Pharmaceutical
Alternative Names: AB 122; GLS 010; GS-0122; WBP 3055; YUTUOLatest Information Update: 09 Jun 2024
At a glance
- Originator WuXi Biologics
- Developer Arcus Biosciences; Gilead Sciences; Guangzhou Gloria Biosciences; Memorial Sloan-Kettering Cancer Center; Strata Oncology; Taiho Pharmaceutical; UCLAs Jonsson Comprehensive Cancer Center; University of Texas Southwestern Medical Center; Yale University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cervical cancer; Hodgkin's disease
- Phase III Gastrointestinal cancer; Non-small cell lung cancer
- Phase II Biliary cancer; Liposarcoma; Liver cancer; Malignant melanoma; Rectal cancer
- Phase I/II Colorectal cancer; Pancreatic cancer; Solid tumours
- No development reported Cancer; Glioblastoma
- Discontinued Prostate cancer
Most Recent Events
- 02 Jun 2024 Efficacy and adverse events data from the phase Ib/II ARC-9 trial in Colorectal cancer released by Gilead Sciences
- 01 Jun 2024 Efficacy and adverse events data from the phase II EDGE-Gastric trial in Gastrointestinal cancer released by Gilead Sciences and Arcus Biosciences
- 31 May 2024 Efficacy and adverse events data from a phase II trial in Cervical cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)